Expression of HBME-1,CK19 and CD117 in papillary thyroid carcinoma and its significance
10.3969/j.issn.1673-4130.2016.20.009
- VernacularTitle:HBME-1、CK19和CD117在甲状腺乳头状癌表达的临床病理意义
- Author:
Zheng ZENG
;
Ruiping LI
;
Min ZHAO
;
Yanhua WEI
;
Zhongyuan SHI
- Publication Type:Journal Article
- Keywords:
thyroid carcinoma;
immunohistochemistry;
HBME-1;
CK19;
CD117
- From:
International Journal of Laboratory Medicine
2016;37(20):2825-2827,2830
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of three antibodies in the differential diagnosis of papillary thyroid carcinoma ,by de‐tecting the expression of HBME‐1 ,CK19 and CD117 in papillary thyroid cacinoma ,thyroid follicular adenoma and Hashimoto′s thy‐roiditis tissues .Methods Totally 85 cases were collected from January 2013 to December 2015 ,including papillary thyroid cacino‐ma ,thyroid follicular adenoma and Hashimoto′s thyroiditis .They were immunohistochemical stained by HBME‐1 ,CK19 and CD117 .SPSS16 .0 software was used to analyze the relationship between the staining results with different pathological changes . Results The positive rates of HBME‐1 ,CK19 and CD117 were 87 .3% ,98 .2% ,and 7 .3% ,respectively .The positive expression of them in benign and malignant groups had significant difference (P< 0 .05) and their consistency checking Kappa were 0 .582 , 0 .551 ,and 0 .874 ,respectively .Conclusion In the differential diagnosis of papillary thyroid carcinoma and benign lesions ,CD117 is better than HBM E‐1 and CK19 .It′s possible to use a combination of them in practice .
